Literature DB >> 30690783

Tissue-type plasminogen activator neutralizes LPS but not protease-activated receptor-mediated inflammatory responses to plasmin.

Cristina Zalfa1, Pardis Azmoon1, Elisabetta Mantuano1,2, Steven L Gonias1.   

Abstract

Tissue-type plasminogen activator (tPA) activates fibrinolysis and also suppresses innate immune system responses to LPS in bone marrow-derived macrophages (BMDMs) and in vivo in mice. The objective of this study was to assess the activity of tPA as a regulator of macrophage physiology in the presence of plasmin. Enzymatically active and enzymatically inactive (EI) tPA appeared to comprehensively block the response to LPS in BMDMs, including expression of proinflammatory cytokines such as TNF-α and IL-1β and anti-inflammatory cytokines such as IL-10 and IL-1 receptor antagonist. The activity of EI-tPA as an LPS response modifier was conserved in the presence of plasminogen. By contrast, in BMDMs treated with tPA and plasminogen or preactivated plasmin, in the presence or absence of LPS, increased proinflammatory cytokine expression was observed and tPA failed to reverse the response. Plasmin independently activated NF-κB, ERK1/2, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase in BMDMs, which is characteristic of proinflammatory stimuli. Plasmin-induced cytokine expression was blocked by ε-aminocaproic acid, aprotinin, and inhibitors of the known plasmin substrate, Protease-activated receptor-1 (PAR-1), but not by N-methyl-d-aspartate receptor inhibitor, which blocks the effects of tPA on macrophages. Cytokine expression by BMDMs treated with the PAR-1 agonist, TFLLR, was not inhibited by EI-tPA, possibly explaining why EI-tPA does not inhibit macrophage responses to plasmin and providing evidence for specificity in the ability of tPA to oppose proinflammatory stimuli. Regulation of innate immunity by the fibrinolysis system may reflect the nature of the stimulus and a balance between the potentially opposing activities of tPA and plasmin. ©2019 Society for Leukocyte Biology.

Entities:  

Keywords:  NMDA receptor; fibrinolysis; inflammation; plasmin; protease-activated receptor; tissue-type plasminogen activator

Mesh:

Substances:

Year:  2019        PMID: 30690783      PMCID: PMC6430673          DOI: 10.1002/JLB.3A0818-329RRR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  47 in total

1.  Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.

Authors:  P Andrade-Gordon; B E Maryanoff; C K Derian; H C Zhang; M F Addo; A L Darrow; A J Eckardt; W J Hoekstra; D F McComsey; D Oksenberg; E E Reynolds; R J Santulli; R M Scarborough; C E Smith; K B White
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

2.  Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.

Authors:  A Kuliopulos; L Covic; S K Seeley; P J Sheridan; J Helin; C E Costello
Journal:  Biochemistry       Date:  1999-04-06       Impact factor: 3.162

Review 3.  Transcriptional regulation by the phosphorylation-dependent factor CREB.

Authors:  B Mayr; M Montminy
Journal:  Nat Rev Mol Cell Biol       Date:  2001-08       Impact factor: 94.444

4.  Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist.

Authors:  H S Ahn; C Foster; G Boykow; A Stamford; M Manna; M Graziano
Journal:  Biochem Pharmacol       Date:  2000-11-15       Impact factor: 5.858

Review 5.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

6.  The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

Authors:  O Nicole; F Docagne; C Ali; I Margaill; P Carmeliet; E T MacKenzie; D Vivien; A Buisson
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

7.  p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD.

Authors:  H Harada; J S Andersen; M Mann; N Terada; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

8.  Plasmin-induced expression of cytokines and tissue factor in human monocytes involves AP-1 and IKKbeta-mediated NF-kappaB activation.

Authors:  T Syrovets; M Jendrach; A Rohwedder; A Schüle; T Simmet
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

9.  The serine protease plasmin triggers expression of MCP-1 and CD40 in human primary monocytes via activation of p38 MAPK and janus kinase (JAK)/STAT signaling pathways.

Authors:  Ladislav Burysek; Tatiana Syrovets; Thomas Simmet
Journal:  J Biol Chem       Date:  2002-07-01       Impact factor: 5.157

10.  Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis.

Authors:  M A Cunningham; E Rondeau; X Chen; S R Coughlin; S R Holdsworth; P G Tipping
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  9 in total

Review 1.  Functions of the plasminogen receptor Plg-RKT.

Authors:  Lindsey A Miles; Juliana P Vago; Lirlândia P Sousa; Robert J Parmer
Journal:  J Thromb Haemost       Date:  2020-08-19       Impact factor: 5.824

2.  A Soluble PrPC Derivative and Membrane-Anchored PrPC in Extracellular Vesicles Attenuate Innate Immunity by Engaging the NMDA-R/LRP1 Receptor Complex.

Authors:  Elisabetta Mantuano; Pardis Azmoon; Michael A Banki; Christina J Sigurdson; Wendy M Campana; Steven L Gonias
Journal:  J Immunol       Date:  2021-11-22       Impact factor: 5.422

Review 3.  Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.

Authors:  Steven L Gonias
Journal:  Am J Physiol Cell Physiol       Date:  2021-08-18       Impact factor: 5.282

4.  The LRP1/CD91 ligands, tissue-type plasminogen activator, α2-macroglobulin, and soluble cellular prion protein have distinct co-receptor requirements for activation of cell-signaling.

Authors:  Elisabetta Mantuano; Pardis Azmoon; Michael A Banki; Cory B Gunner; Steven L Gonias
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

5.  Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease.

Authors:  Lipsa Das; Michael A Banki; Pardis Azmoon; Donald Pizzo; Steven L Gonias
Journal:  Am J Pathol       Date:  2021-01-17       Impact factor: 4.307

6.  Tissue-type plasminogen activator selectively inhibits multiple toll-like receptors in CSF-1-differentiated macrophages.

Authors:  Lipsa Das; Pardis Azmoon; Michael A Banki; Elisabetta Mantuano; Steven L Gonias
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

7.  Fibrinolysis protease receptors promote activation of astrocytes to express pro-inflammatory cytokines.

Authors:  Paola Pontecorvi; Michael A Banki; Carlotta Zampieri; Cristina Zalfa; Pardis Azmoon; Maria Z Kounnas; Cinzia Marchese; Steven L Gonias; Elisabetta Mantuano
Journal:  J Neuroinflammation       Date:  2019-12-06       Impact factor: 8.322

Review 8.  Roles of the tissue-type plasminogen activator in immune response.

Authors:  Célia Seillier; Pauline Hélie; Gautier Petit; Denis Vivien; Diego Clemente; Brigitte Le Mauff; Fabian Docagne; Olivier Toutirais
Journal:  Cell Immunol       Date:  2021-11-06       Impact factor: 4.868

9.  Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS.

Authors:  Marcel F Leyton-Jaimes; Patrik Ivert; Jan Hoeber; Yilin Han; Adam Feiler; Chunfang Zhou; Stanislava Pankratova; Varda Shoshan-Barmatz; Adrian Israelson; Elena N Kozlova
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.